Satpati, Drishty’s team published research in Cancer Biotherapy and Radiopharmaceuticals in 2009 | CAS: 56523-59-2

Cancer Biotherapy and Radiopharmaceuticals published new progress about Blood. 56523-59-2 belongs to class bromides-buliding-blocks, name is 15-Bromopentadecanoic acid, and the molecular formula is C15H29BrO2, Application of 15-Bromopentadecanoic acid.

Satpati, Drishty published the artcilePreparation and Evaluation of 99mTc(CO)3-Labeled Pentadecanoic Acid Derivative and Its Suspension in Lipiodol, Application of 15-Bromopentadecanoic acid, the main research area is bromopentadecanoic acid lipiodol stability.

Transarterial embolization by the intra-arterial administration of 131I-lipiodol is a modality used in the treatment of liver cancer. Long-chain fatty acids, being highly lipophilic, are also known to localize in the liver, thus constituting favorable vectors for this modality of treatment. Toward this, we envisaged the derivatization of 15-bromopentadecanoic acid, rendering it suitable for incorporation of a tridentate chelating moiety, for radiolabeling with the [99mTc(CO)3(H2O)3]+ precursor. The complex prepared, being lipophilic, was expected to behave as a lipiodol surrogate. The radiolabeled complex could be obtained in >95% radiochem. yield, as characterized by high-performance liquid chromatog. The i.v. injection of the radiolabeled complex in mice resulted in 23.5% ± 4.3% uptake of injected dose (ID) organ in the liver at 3 h postinjection. However, the uptake of the lipiodol suspension of the complex at 3 h postinjection in the liver was found to be 43.8 ± 13.4% ID/organ, when injected via the portal vein.

Cancer Biotherapy and Radiopharmaceuticals published new progress about Blood. 56523-59-2 belongs to class bromides-buliding-blocks, name is 15-Bromopentadecanoic acid, and the molecular formula is C15H29BrO2, Application of 15-Bromopentadecanoic acid.

Referemce:
Bromide – Wikipedia,
bromide – Wiktionary